Pune, India, October 2018/MRFR Press Release/- Market Research Future has published a half-cooked research report on the Global Rapid Sterility Testing Market.

Rapid Sterility Testing Market Highlights

The Rapid Sterility Testing Market is projected to reach USD 4.26 Billion by 2032 at 8.20% CAGR during the forecast period 2023-2032. Rapid sterility testing used to detect microbial contamination in given biologic sample. It is an alternative method for sterility testing.

Increasing R&D expense and new product launches are expected to drive the growth of the market. According to the Center for Drug Evaluation and Research, in 2017, about 46 novel drug approvals were the 22 novel drug approval in 2016. On the other hand, the availability of the alternative traditional method can restrain the market growth over the assessment period.

Regional Analysis

Geographically, the Americas is expected to dominate the global market owing to the presence of well-established players and growth in pharmaceutical and medical device companies. Europe is expected to hold the second largest position in the global market. Asia-Pacific is expected to be the fastest growing market owing to the increasing adoption of the technologies. Furthermore, the Middle Eastern and African region is expected to account for the least market share in the global market.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Rapid Sterility Testing Market Research Report

Segmentation

The global rapid sterility testing market has been segmented into product, technology, and application.

Based on product, the market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to account for the largest share and fastest growing segment of the global market in 2017.

Based on technology, the market is segmented into membrane filtration, ATP bioluminescence, and others. The ATP bioluminescence segment is expected to account for the largest share segment of the global market in 2017.

Based on application, has been segmented into pharmaceutical and biological manufacturing, medical device manufacturing, other end users.

Key Players

Some of the prominent players in the global rapid sterility testing market are Charles River Laboratories, Inc. (US), Gibraltar Laboratories (US), Merck KGaA (Germany), Rapid Micro Biosystems, Inc. (US), bioMérieux (France), Eurofins Scientific (Luxembourg), Becton, Dickinson and Company (US), FOCUS Laboratories (US), Sartorius AG (Germany), and Thermo Fisher Scientific (US).